| abstract |
FIELD: biotechnology. n SUBSTANCE: present invention relates to genetics. Method for evaluating of risk of thromboembolic episode occurrence or diagnostics or presence of such disease or episode, based on presence of serpin A10 (protein Z inhibitor) Arg67Stop (rs2232698), serpin C1 (antithrombin) Ala384Ser (Cambridge II), factor XII C46T (rs1801020), factor XIII Val34Leu (rs5985), factor II (prothrombin) G20210A (rs1799963), factor V Leiden Arg506Gln (rs6025), factor V Cambridge Arg306Thr, factor V306Hong Kong ArgGly, AB0 blood group rs8176719, blood group ABO rs7853989, rs8176743 and rs8176750. Besides, method is disclosed of identification of individual, requiring therapeutic treatment with anticoagulant and/or antithrombin, or preventive treatment with anticoagulant and/or antithrombin, based on presence of at least one allele of each of said polymorphous variants. n EFFECT: present invention can find further application in therapy of thromboembolic diseases. n 7 cl, 2 dwg, 8 tbl, 1 ex |